[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583167":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":79,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Wonju Severance Christian Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"HFNC-NIV","EXPERIMENTAL","Participants first use HFNC for six weeks, then switch to NIV for six weeks",[13,14],"Device: High-Flow Nasal Cannula","Device: Noninvasive Ventilation",{"label":16,"type":10,"description":17,"interventionNames":18},"NIV-HFNC","Participants first use NIV for six weeks, then switch to HFNC for six weeks",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","High-Flow Nasal Cannula","To compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD.",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Noninvasive Ventilation","to compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD",[9,16],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Sang-Ha Kim","CONTACT","82-33-741-0926","sanghakim@yonsei.ac.kr",[37],{"facility":5,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":25,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Wŏnju","Gangwondo","26426","South Korea",{"type":43,"coordinates":44},"Point",[45,46],127.94528,37.35139,{"lat":46,"lon":45},[49,53],{"name":50,"role":33,"phone":51,"phoneExt":25,"email":52},"Hyo Jin Kim","82-33-741-0927","chestcrc0927@gmail.com",{"name":32,"role":54,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":32,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Professor","100583167","home-high-flow-nasal-cannula-vs-noninvasive-ventilation-for-stable-chronic-respiratory-failure-100583167",false,"NCT06872801","Home High-Flow Nasal Cannula vs. Noninvasive Ventilation for Stable Chronic Respiratory Failure","Comparison of the Effects of Home High-Flow Nasal Cannula Therapy and Noninvasive Ventilation in Patients With Stable Chronic Hypercapnic Respiratory Failure","Inclusion Criteria:\n\n* Adult aged 40 years or older\n* Diagnosed with COPD\n* Arterial blood gas test, pCO2 \\> 45 mmHg at stable status\n* A person who can read or write in Korean\n* Written informed consent to participate in this study\n\nExclusion Criteria:\n\n* A person who disagrees with the content of a informed consent\n* Those who have difficulty wearing NIV or HFNC\n* Cognitive impairment or apsychiatric disorder\n* Hypoxic or hypercapnic exacerbation within the previous four weeks","ALL","40 Years",{"count":67,"type":68},38,"ESTIMATED","INTERVENTIONAL",[71],"NA","The goal of this clinical trial is to compare the effects of home high-flow nasal cannula (HFNC) therapy and noninvasive ventilation (NIV) in patients with stable chronic hypercapnic respiratory failure. The main questions it aims to answer are:\n\n* Does HFNC or NIV reduce blood carbon dioxide levels more effectively?\n* How well do patients tolerate and adhere to each therapy?\n* Are there differences in oxygen saturation, respiratory rate, and quality of life between the two treatments?\n\nParticipants Will:\n\n* Use either HFNC (myAirvo2®) or NIV (Trilogy Evo®) every night for at least 4 hours over a 6-week period.\n* Visit the hospital for checkups and arterial blood gas tests at the end of each 6-week period.\n* Switch to the alternate device after six weeks as part of the crossover study design.\n* Have their device usage recorded and analyzed.",[74],"Stable Chronic Hypercapnic Respiratory Failure",[76,27,22,77,78],"Chronic Hypercapnic Respiratory Failure","Randomized Controlled Trial","Crossover Design","NOT_YET_RECRUITING","2025-03-10",{"date":82,"type":83},"2025-03-12","ACTUAL",{"date":85,"type":68},"2025-03",{"date":87,"type":68},"2026-06",{"name":5,"class":6},1]